JP2016516059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516059A5 JP2016516059A5 JP2016503067A JP2016503067A JP2016516059A5 JP 2016516059 A5 JP2016516059 A5 JP 2016516059A5 JP 2016503067 A JP2016503067 A JP 2016503067A JP 2016503067 A JP2016503067 A JP 2016503067A JP 2016516059 A5 JP2016516059 A5 JP 2016516059A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 23
- 108090001123 antibodies Proteins 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 2
- 102100014650 MICA Human genes 0.000 claims 2
- 101700060941 MICA Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 2
- 229960000237 Vorinostat Drugs 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960002438 carfilzomib Drugs 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 229940121372 histone deacetylase inhibitors Drugs 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 229960003452 romidepsin Drugs 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
- QRGHOAATPOLDPF-BYICEURKSA-N 2-[(1R,5S)-6-[(6-fluoroquinolin-2-yl)methylamino]-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H](C2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-BYICEURKSA-N 0.000 claims 1
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims 1
- -1 AN-9 Chemical compound 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 229950005837 Entinostat Drugs 0.000 claims 1
- YALNUENQHAQXEA-UHFFFAOYSA-N Givinostat Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000003964 Histone deacetylases Human genes 0.000 claims 1
- 108090000353 Histone deacetylases Proteins 0.000 claims 1
- 229960003648 Ixazomib Drugs 0.000 claims 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N Salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000010445 mica Substances 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108010091666 romidepsin Proteins 0.000 claims 1
- 150000004666 short chain fatty acids Chemical class 0.000 claims 1
- 235000021391 short chain fatty acids Nutrition 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (20)
- MHCクラスI型ポリペプチド関連性配列A(MICA)に免疫特異的に結合する抗体またはそれらの抗原結合フラグメントであって、前記抗体は、
配列番号:154に示すアミノ酸配列を含む重鎖可変領域(VH)CDR1、
配列番号:156に示すアミノ酸配列を含むVH CDR2、および
配列番号:158に示すアミノ酸配列を含むVH CDR3、
またはV H CDR1、V H CDR2および/またはV H CDR3において5以下の保存的アミノ酸置換を有するそれらの変異体
を含む、抗体またはそれらの抗原結合フラグメント。 - 前記抗体または抗原結合フラグメントが、
配列番号:161に示すアミノ酸配列を含む軽鎖可変領域(VL)CDR1、
配列番号:163に示すアミノ酸配列を含むVL CDR2、および
配列番号:165に示すアミノ酸配列を含むVL CDR3、
またはVL CDR1、V L CDR2および/またはV L CDR3において5以下の保存的アミノ酸置換を有するそれらの変異体
を含む、請求項1に記載の抗体または抗原結合フラグメント。 - 前記VH領域が
配列番号:154を含むVH CDR1;
配列番号:156を含むVH CDR2;および
配列番号:158を含むVH CDR3
を含む、請求項1または2に記載の抗体または抗原結合フラグメント。 - 前記VL領域が
配列番号:161を含むVL CDR1、
配列番号:163を含むVL CDR2、および
配列番号:165を含むVL CDR3
を含む、請求項1〜3のいずれかに記載の抗体または抗原結合フラグメント。 - 前記VH 領域のFR1、FR2、FR3、FR4領域が、配列番号:150に示されるVHの対応するFR1、FR2、FR3、FR4領域に対し、少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%同一性を有するアミノ酸配列を含む、請求項1〜4のいずれかに記載の抗体または抗原結合フラグメント。
- 前記VL 領域のFR1、FR2、FR3、FR4領域が、配列番号:152に示されるVLの対応するFR1、FR2、FR3、FR4領域に対し、少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%同一性を有するアミノ酸配列を含む、請求項2〜5のいずれかに記載の抗体または抗原結合フラグメント。
- 前記VH領域が、CDR内ではない残基において5以下の保存的アミノ酸置換を有する配列番号:150に示すアミノ酸配列またはその変異体を含む、請求項1〜6のいずれかに記載の抗体または抗原結合フラグメント。
- 前記VL領域が、CDR内ではない残基において5以下の保存的アミノ酸置換を有する配列番号:152に示すアミノ酸配列またはその変異体を含む、請求項1〜7のいずれかに記載の抗体または抗原結合フラグメント。
- 配列番号:150に示すアミノ酸配列を有するVH 領域および配列番号:152に示すアミノ酸配列を有するVL 領域を含む、請求項1〜8のいずれかに記載の抗体または抗原結合フラグメント。
- 前記抗体または抗原結合フラグメントがヒト、ヒト化またはキメラである、請求項1〜9のいずれかに記載の抗体または抗原結合フラグメント。
- 請求項1〜10のいずれかに記載の抗体または抗原結合フラグメントを含む医薬組成物。
- 1つ以上のさらなる薬剤を含む、請求項11に記載の医薬組成物。
- 化学療法、放射線療法、サイトカイン、ケモカインおよび他の生体シグナル伝達分子、腫瘍特異的ワクチン、細胞癌ワクチン(例えば、GM−CSF形質導入癌細胞)、腫瘍特異的モノクローナル抗体、自己および同種異系の幹細胞レスキュー(例えば、移植片対腫瘍効果を増強させる)、分子標的療法、抗脈管形成療法、および遺伝子治療からなる群から選択される癌の処置のために使用される1つ以上のさらなる薬剤を含む、請求項12に記載の医薬組成物。
- 前記1つ以上のさらなる薬剤が、ヒドロキサム酸、ボリノスタット、スベロイルアニリドヒドロキサム酸(SAHA、トリコスタチンA(TSA)、LAQ824、パノビノスタット(LBH589)、ベリノスタット(PXD101)、ITF2357 italfarmaco SpA、環状テトラペプチド、デプシペプチド(ロミデプシン、FK228)、ベンズアミド;entinostat(SNDX−275/MS−275)、MGCD0103、短鎖脂肪酸、バルプロ酸、フェニル酪酸、AN−9、pivanex、CHR−3996、およびCHR−2845からなる群から選択されるヒストンデアセチラーゼインヒビター(HDAC);ボルテゾミブ、NPI−0052、カーフィルゾミブ(PR−171)、CEP 18770、およびMLN9708からなる群から選択されるプロテアソーム阻害剤;抗−CTLA−4抗体またはペプチド;抗−PD−1抗体またはペプチド;抗−PDL−1抗体またはペプチド;抗−OX40抗体またはペプチド;抗−GITR抗体またはペプチド;抗−LAG−3抗体またはペプチド;および抗−TIM−3抗体またはペプチドを含む、請求項12に記載の医薬組成物。
- 対象において癌の処置における使用のための、請求項11〜14のいずれか一項に記載の医薬組成物。
- 請求項1〜10のいずれかに記載の抗体または抗原結合フラグメントをコードする単離された核酸。
- 配列番号:149に対し少なくとも約75%、80%、90%、95%、99%または100%配列同一性を有するヌクレオチド配列を含む、請求項16に記載の単離された核酸。
- 配列番号:151に対し少なくとも約75%、80%、90%、95%、99%または100%配列同一性を有するヌクレオチド配列を含む、請求項16または17に記載の単離された核酸。
- 請求項16〜18のいずれか一項に記載の核酸を含むベクター。
- 前記ベクターがプラスミドまたはウイルスベクターである、請求項19に記載のベクター。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792034P | 2013-03-15 | 2013-03-15 | |
US61/792,034 | 2013-03-15 | ||
US201361913198P | 2013-12-06 | 2013-12-06 | |
US61/913,198 | 2013-12-06 | ||
PCT/US2014/029348 WO2014144791A2 (en) | 2013-03-15 | 2014-03-14 | Therapeutic peptides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016516059A JP2016516059A (ja) | 2016-06-02 |
JP2016516059A5 true JP2016516059A5 (ja) | 2017-04-13 |
JP6397886B2 JP6397886B2 (ja) | 2018-09-26 |
Family
ID=50588904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016503067A Active JP6397886B2 (ja) | 2013-03-15 | 2014-03-14 | 治療用ペプチド |
Country Status (15)
Country | Link |
---|---|
US (1) | US10745483B2 (ja) |
EP (2) | EP2970908B1 (ja) |
JP (1) | JP6397886B2 (ja) |
KR (1) | KR20150130462A (ja) |
CN (1) | CN105142668B (ja) |
AU (1) | AU2014228502A1 (ja) |
BR (1) | BR112015021576A2 (ja) |
CA (1) | CA2907249A1 (ja) |
EA (1) | EA201591559A1 (ja) |
ES (1) | ES2779398T3 (ja) |
HK (1) | HK1219983A1 (ja) |
MX (1) | MX2015011075A (ja) |
NZ (1) | NZ629816A (ja) |
SG (1) | SG11201506766PA (ja) |
WO (1) | WO2014144791A2 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ721184A (en) | 2011-09-30 | 2018-08-31 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
EP2970908B1 (en) | 2013-03-15 | 2019-12-25 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
ES2755129T3 (es) | 2013-12-06 | 2020-04-21 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
WO2015139020A2 (en) * | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
US10744157B2 (en) | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
BR112018010705A8 (pt) | 2015-12-04 | 2019-02-26 | Dana Farber Cancer Inst Inc | vacinação com o domínio mica/b alfa 3 para o tratamento de câncer |
KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) * | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CN110267678A (zh) * | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
US20220363766A1 (en) * | 2019-10-09 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cytotoxic t cell resistant tumors |
CN113637077B (zh) * | 2021-10-14 | 2021-12-24 | 尚健单抗(北京)生物技术有限公司 | 一种抗mica的抗体及其应用 |
WO2023196598A2 (en) * | 2022-04-08 | 2023-10-12 | D2M Biotherapeutics Limited | Anti-mica/b antibodies and uses thereof |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
EP0351410A1 (en) | 1987-03-18 | 1990-01-24 | 3i RESEARCH EXPLOITATION LIMITED | Complement-binding peptide |
GB8709290D0 (en) | 1987-04-16 | 1987-05-20 | Secretary Trade Ind Brit | Precision motion slideways |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998019167A2 (en) | 1996-10-29 | 1998-05-07 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
EP1252192B1 (en) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Enhancing the circulating half-life of antibody-based fusion proteins |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002068615A2 (en) | 2001-02-28 | 2002-09-06 | Fred Hutchinson Cancer Research Center, Inc. | Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives |
US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
US6566208B2 (en) | 2001-07-25 | 2003-05-20 | Chartered Semiconductor Manufacturing Ltd. | Method to form elevated source/drain using poly spacer |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003089616A2 (en) | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
ATE394674T1 (de) | 2002-04-22 | 2008-05-15 | Univ Florida | Funktionalisierte nanopartikel und verwendungsverfahren |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
AU2004259398A1 (en) | 2003-06-27 | 2005-02-03 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
CN1317861C (zh) | 2003-07-21 | 2007-05-23 | 中兴通讯股份有限公司 | 无线局域网接入点设备虚拟局域网的实现方法 |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
DK1776384T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
CA2584859C (en) | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
US20080148432A1 (en) | 2005-12-21 | 2008-06-19 | Mark Scott Abad | Transgenic plants with enhanced agronomic traits |
EP2284194A1 (en) | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
JP2009514528A (ja) | 2005-11-03 | 2009-04-09 | フレッド ハッチンソン キャンサー リサーチ センター | Nkg2d陽性cd4+細胞による免疫応答の負の免疫調節法 |
DE102006009847A1 (de) | 2006-03-01 | 2007-09-06 | Sweredjuk, Robert, Dr. | Verfahren von Absorbieren von Schadstoffen und Gerüchen |
AU2007284878B2 (en) | 2006-08-07 | 2013-01-17 | President And Fellows Of Harvard College | Protein matrix vaccines and methods of making and administering such vaccines |
US20110060120A1 (en) | 2006-09-08 | 2011-03-10 | Obeid Michel Sarkis | Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57 |
WO2008036981A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Research, Inc. | Methods for treating mica-related disorders |
CA2664567C (en) | 2006-10-04 | 2016-04-26 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
EP2150565A2 (en) | 2007-04-23 | 2010-02-10 | Fred Hutchinson Cancer Research Center | NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5 |
NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US8182809B1 (en) | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
US8207497B2 (en) | 2009-05-08 | 2012-06-26 | Ionsense, Inc. | Sampling of confined spaces |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
KR101688522B1 (ko) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
CN102911270A (zh) | 2011-08-05 | 2013-02-06 | 浙江大学 | 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法 |
NZ721184A (en) | 2011-09-30 | 2018-08-31 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
US10577416B2 (en) | 2012-02-07 | 2020-03-03 | Innate Pharma, S.A. | Mica binding agents |
EP2970908B1 (en) | 2013-03-15 | 2019-12-25 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US9572898B2 (en) | 2013-09-09 | 2017-02-21 | Seton Hall University | Functionalized fluorine containing phthalocyanine molecules |
ES2755129T3 (es) | 2013-12-06 | 2020-04-21 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos |
WO2015139020A2 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
EP3145953A1 (en) | 2014-05-21 | 2017-03-29 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti bip or anti mica antibodies |
-
2014
- 2014-03-14 EP EP14720000.0A patent/EP2970908B1/en active Active
- 2014-03-14 CA CA2907249A patent/CA2907249A1/en not_active Abandoned
- 2014-03-14 ES ES14720000T patent/ES2779398T3/es active Active
- 2014-03-14 MX MX2015011075A patent/MX2015011075A/es unknown
- 2014-03-14 SG SG11201506766PA patent/SG11201506766PA/en unknown
- 2014-03-14 EP EP19207376.5A patent/EP3666886A1/en not_active Withdrawn
- 2014-03-14 NZ NZ629816A patent/NZ629816A/en not_active IP Right Cessation
- 2014-03-14 BR BR112015021576A patent/BR112015021576A2/pt not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/029348 patent/WO2014144791A2/en active Application Filing
- 2014-03-14 EA EA201591559A patent/EA201591559A1/ru unknown
- 2014-03-14 CN CN201480015732.6A patent/CN105142668B/zh not_active Expired - Fee Related
- 2014-03-14 JP JP2016503067A patent/JP6397886B2/ja active Active
- 2014-03-14 AU AU2014228502A patent/AU2014228502A1/en not_active Abandoned
- 2014-03-14 US US14/776,968 patent/US10745483B2/en active Active
- 2014-03-14 KR KR1020157028477A patent/KR20150130462A/ko not_active Application Discontinuation
-
2016
- 2016-07-11 HK HK16108069.1A patent/HK1219983A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016516059A5 (ja) | ||
JP2014532053A5 (ja) | ||
HRP20170494T1 (hr) | Terapeutski peptidi | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
RU2019105702A (ru) | Антитело против lag-3 | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
RU2014133410A (ru) | Антитело к blys | |
PE20141017A1 (es) | Anticuerpos del cea | |
JP2018519356A5 (ja) | ||
RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
WO2016150899A3 (en) | Anti-ceacam6 antibodies and uses thereof | |
RU2018121413A (ru) | Антитело ANTI-PCSK9 и его применение | |
EA201692530A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
RU2015146419A (ru) | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl | |
RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
PE20140247A1 (es) | Anticuerpos anti-cd38 | |
PE20191487A1 (es) | Anticuerpos anti-gitr y metodos de uso de los mismos | |
EA201692148A1 (ru) | Гуманизированные антитела против ceacam1 |